2637.HK · HAIXI PHARMA
Hong Kong · RS rating 34 · As of 2026-11-03
| Price | 142.40 HKD |
|---|---|
| 1-day change | +0.9% |
| RS rating (overall / 1M / 3M / 12M) | 34 / 30 / 21 / 83 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 30 / 24 / 6 |
| Industry group (rank) | Pharma & Biotech (27) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +49.3% |
| Market cap (USD) | $1.4B |